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Introduction: Very few cases of scar sarcoidosis affecting the eyes and bone together have been reported in the
last few years.
Case presentation: We report a case of a 49-year-old Spanish man with recurrent bilateral granulomatous uveitis and a
fistulous nodular lesion in the left pre-tibial region (scar granuloma) on the site of an 8-year-old scar. He presented with
bilateral hilar adenopathies and elevation of inflammatory markers and angiotensin-converting enzyme. A histologically
confirmed sarcoid of the tibia with a radiologic appearance unusual for long tubular bone involvement was observed.
He also had bilateral ophthalmologic involvement.
Conclusions: Sarcoidosis is a disease of unknown cause histologically characterized by non-caseating granulomas that
can involve any organ or tissue. Osseous sarcoidosis is a relatively rare presentation. However, on the basis of cases
reported in the literature, sarcoid lesions on bones are generally asymptomatic. Biologic agents are considered an
alternative therapy for sarcoidosis resistant to conventional treatment.Introduction
Scar sarcoidosis of the tibia is considered a rare disease.
It is usually described in old scars (10 years) [1], and it is
more common in the upper extremities and facial area,
together with an exacerbation of sarcoidosis symptoms
(Löfgren syndrome) affecting the eyes or, in our patient,
bone [2].
In the last few years, very few cases of scar sarcoidosis
affecting the eyes or bone have been described in the lit-
erature. The appropriate treatment consists of steroids
with gradual dose increases until the condition is con-
trolled, followed by immunosuppressive agents such as
methotrexate and azathioprine for control of inflamma-
tion [3]. Several studies support the use of monoclonal
antibodies against tumor necrosis factor α, mostly inflix-
imab, in the treatment of pulmonary sarcoidosis, uveitis,
cutaneous sarcoidosis including lupus pernio, and neu-
rosarcoidosis [4–12]. Nevertheless, evidence is based on
small series or on case reports. We describe a case of a
patient with recurrent bilateral granulomatous uveitis to-
gether with a fistulous nodular lesion in the left pre-* Correspondence: npalmou@hotmail.com
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A 49-year-old Spanish man was referred to our hospital by
an ophthalmologist in June 2010 with a symptom of red
eyes. A uveitis protocol was implemented. A chest X-ray
was ordered. The X-ray showed mediastinal adenopathy,
for which the patient was referred to the respiratory medi-
cine department. The results of his respiratory function
tests were normal, so a high-resolution computed tomo-
graphic (CT) scan of the lungs was ordered. As he had no
interstitial disease, he was diagnosed with stage I pulmon-
ary sarcoidosis, and no systemic treatment was prescribed.
A sacroiliac X-ray and a magnetic resonance imaging scan
showed sclerotic changes that appeared chronic. No bone
edema was observed. His human leukocyte antigen B27
test was negative, and his angiotensin-converting enzyme
(ACE) level was elevated. His physical examination showed
that he was hemodynamically stable and afebrile and that
his overall health status was good. His musculoskeletal
examination revealed a raised fistulous erythematous le-
sion with serous bloody secretion. He had no erythema orThis article is distributed under the terms of the Creative Commons
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tous bullous lesions were found on his lower extremities.
The patient’s blood examination results showed ele-
vated acute-phase reactants (erythrocyte sedimentation
rate, C-reactive protein) but no leukocytosis or left
shift. His kidney and liver function, electrolytes and
clotting were normal. His ACE level was somewhat ele-
vated, and his urine sediment was normal. The results
of his serologic tests were negative (hepatitis, HIV, ru-
bella, cytomegalovirus, Epstein-Barr virus, Toxoplasma,
Treponema pallidum, Borrelia, Mycoplasma and Chla-
mydia). To rule out the possibility of tuberculosis, a
Mantoux test (negative) and serial urine cultures with
auramine staining (negative) were ordered. His high-
resolution CT scan was compatible with stage I sarcoid-
osis (bilateral hilar and mediastinal adenopathies).
The patient was also being followed in the internal
medicine department for a possible infection after a le-
sion resembling osteomyelitis was observed on a CT
scan of the left lower limb (Fig. 1). A biopsy was taken,
the result of which was compatible with foreign body
granuloma. Culture results were negative, and no ma-
lignant cells were found, although Pseudomonas and
Corynebacterium spp. were isolated in the fistulous se-
cretion. Antibiotics were prescribed for 6 months. With
no improvement, the patient was referred to the
rheumatology department. A second pre-tibial skin bi-
opsy showed a giant-cell granuloma. Ziehl-Neelsen and
periodic acid–Schiff staining results were negative
(Fig. 2).
At the same time that the lesion on the patient’s left
leg worsened, his eye symptoms returned, so he wasFig. 1 A lesion resembling osteomyelitis on a computed tomographic scanreferred by the ophthalmology department to be
assessed for immunosuppressant treatment. Despite im-
provement with topical and oral corticosteroid therapy,
his symptoms persisted.
Treatment was started with prednisone, with the dose
being gradually increased from 15mg/day to 30mg/day.
The patient showed a very good clinical response. He
remained afebrile, his malleolar swelling decreased and
his fistulous lesion progressively disappeared. Treatment
with 15mg methotrexate was immediately prescribed as
a measure to avoid corticosteroid use to a certain extent
and to reduce the dose by up to 7.5mg every 2 weeks.
The patient had a successful recovery.
The patient was subsequently followed in the rheuma-
tology, trauma and internal medicine departments,
where he was found to be asymptomatic with no further
attacks of uveitis. The lesion did not recur.
Discussion
Sarcoidosis is a multi-systemic granulomatous disease of
unknown etiology that particularly affects young people.
Its most common symptoms are bilateral hilar adenopa-
thies, pulmonary infiltrates and skin and eye lesions. It is
also characterized by the formation of non-caseating
granulomas [13–15].
When bone is affected, the patient is normally asymp-
tomatic. The presentation of sarcoidosis is described as
lytic and cystic lesions on the fingers and toes (42%) that
do not generally require treatment. However, soft tis-
sues can be affected, with formation of fistulas on the
skin that require curettage and corticosteroid therapy
or chloroquine, which generally work very well withof the left lower limb
Fig. 2 Epithelioid granuloma with multi-nucleated giant cells
without necrosis or acid-fast rod microorganisms (AFB)
microorganisms examined using Ziehl-Neelsen and periodic
acid–Schiff staining techniques
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1–13%, and bone lesions due to sarcoid granulomas are
diagnosed by biopsy [3, 13–16].
Approximately 38% of all cases of erythema nodosum
are related to sarcoidosis in Löfgren syndrome, and they
occur with skin lesions such as plaques, nodules and
scars [17–19]. When the eyes are affected, the cases are
usually bilateral, recurrent or chronic and secondary and
requires ruling out other systemic causes.
In 50−70% of sarcoidosis cases related to other sites,
the eyes are also involved and the eye condition often
becomes chronic and recurring [20–22].
ACE values are elevated in 88% of patients with active
sarcoidosis, but using these levels to diagnose the disease
can be misleading because approximately 10% of results
are false positives and about 40% are false negatives.
However, measuring the ACE level is useful to monitor
disease progression [15].
The cornerstone treatment is based on corticosteroids
with gradual dose decreases until the disease is con-
trolled. If the patient’s sarcoidosis is still active, immuno-
suppressive agents followed by second-line treatments
such as methotrexate or azathioprine, as well as biologic
agents such as infliximab, can be used for several clinical
manifestations, although the evidence for these is based
on small studies, so more extensive studies are needed
to establish use of these treatments [10, 14, 23].
Four other scar sarcoidosis clinical cases have been re-
ported to date. Scar sarcoidosis was found in all of
them. This is an uncommon but specific manifestation
of sarcoidosis. One of the patients developed scar sar-
coidosis on his right finger [24]. Another patient, who
had Löfgren syndrome, developed sarcoidosis after a
forehead scar [25]. In two cases, sarcoidosis occurred
after a herpes zoster scar. One occurred with a dissemi-
nated scar that predicted pulmonary involvement [26].Conclusions
To the best of our knowledge, this is the first case of
tibia sarcoidosis scar reported in the literature. Sarcoid-
osis generally responds well to corticosteroid therapy,
but it is not self-limiting and often also requires the use
of an immunosuppressant to avoid corticosteroids and
to achieve remission without recurrence. When the eyes
are involved, it is often related to other sarcoidosis
symptoms. If the disease is not controlled, these symp-
toms will not be controlled either. Sarcoidosis is usually
treated with methotrexate, cyclosporine, azathioprine or
cyclophosphamide. New biologic therapies have also
been used, with infliximab producing the best response,
although the number of studies on the subject is limited
[23, 27, 28].
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